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Treatment with valproic acid (VPA), despite its efficacy in bipolar disorder and epilepsy, may be associated with thrombocytopenia.The risk factors for VPA-associated thrombocytopenia include female gender, advanced age, and high doses.Future research should define the clinical impact of VPA-associated thrombocytopenia (e.g., the risk of hemorrhagic stroke during VPA treatment).

Introduction {#Sec1}
============

Valproic acid (VPA) was synthesized by the American chemist Beverly S. Burton more than a century ago as a derivative of valeric acid, a component of the herbal medicine *Valeriana officinalis*. It was mainly used as a solvent for organic compounds until 1963, when Pierre Eymard discovered that all solutions containing valproate had anticonvulsant properties \[[@CR1]\]. Rapidly, VPA came into regular clinical usage in France (late 1960s) as well as in the UK (1972) and the US (1978). Currently, VPA is widely prescribed as an antiepileptic drug and mood stabilizer. Its effectiveness in bipolar disorder (BD) was firstly demonstrated by Lambert and colleagues in 1966 \[[@CR1]\], and now international guidelines recommend its use for acute and long-term treatment of BD \[[@CR2]\]. Of note, VPA monotherapy has showed the same effectiveness as lithium and atypical antipsychotics for the treatment of acute mania, but with a better tolerability \[[@CR2]\]. VPA can be currently considered as the first-line option for almost all epileptic syndromes (focal seizures with or without secondary generalization), including childhood ones.

Despite its long-standing usage, the mechanism of action of VPA is still debated. Studies originally focused on its ability to dampen neuronal hyper-excitability by potentiating the inhibition of neurotransmission, as a result of its chemical similarity to gamma-aminobutyric acid (GABA). More recently, some research has shown further pharmacodynamic properties of the compound, including a direct effect on voltage-gated sodium channels or the disruption of the membrane environment of sodium channels \[[@CR3]\]. VPA also appears to regulate the excitatory activity of NMDA glutamate receptors and modulates the epigenetic regulation of neuronal gene expression by non-selective inhibition of histone deacetylase \[[@CR1]\].

Common side effects of VPA include fatigue, tremor, sedation, gastrointestinal symptoms, and weight gain; these side effects are mostly dose or serum concentration dependent and can be minimized by dosage modification. The teratogenic risks of the compound are well documented in the literature. VPA adverse reactions can be classified as neurological, metabolic, endocrine, and hematological ones. We decided to focus on thrombocytopenia because this side effect often goes unnoticed and can suddenly manifest with life-threatening events such as hemorrhagic stroke \[[@CR4]\]. The purpose of the present manuscript is therefore to provide a critical overview about the risk of thrombocytopenia in subjects treated with VPA. To our knowledge, there are no recent comprehensive reviews about this specific topic. From a statistical point of view, thrombocytopenia is defined as a platelet count of \< 150,000 per microliter (the 2.5th lower percentile); however, emergency treatment is required in case of a count \< 50,000 per microliter. In some research, a more restricted definition of thrombocytopenia is used: a platelet count of \< 100,000 or 130,000 per microliter.

Methods {#Sec2}
=======

A careful search of articles on MEDLINE, PsycINFO, Isi Web of Knowledge, and Medscape was performed by matching the words 'valproate' and 'valproic acid' with 'thrombocytopenia'. After excluding duplicates, 159 abstracts were screened. Nine papers were finally considered after excluding off-topic research (e.g., about VPA efficacy on mood symptoms or epilepsy), case reports and case series, and articles with pediatric populations. Children were excluded because they are thought to have a different risk of thrombocytopenia as a consequence of pharmacological treatment \[[@CR5]\]. Only papers from the last 30 years (1987--2017) were included as available information was not always accurate in most of the previous articles.

Results {#Sec3}
=======

It is currently known that thrombocytopenia can occur in 5--18% of patients taking VPA \[[@CR6], [@CR7]\], and is more frequently observed in women and elderly subjects \[[@CR8]--[@CR10]\]. Moreover, a lower baseline platelet count is reported to be an additional risk factor for thrombocytopenia, and VPA dose influences the final platelet count in a proportional way \[[@CR11]--[@CR13]\].

The exact mechanism through which valproate can cause thrombocytopenia is unknown; it can be caused by an increased disruption of platelets as well as by the formation of autoantibodies destroying platelets or by decreased production due to a direct toxic effect on bone marrow \[[@CR3]\]. Laboratory studies have shown that VPA perturbs hematopoietic homeostasis through erythroid differentiation inhibition and activation of the myelo-monocytic pathway \[[@CR3]\]. The most frequent clinical manifestations of thrombocytopenia are represented by prolonged bleeding time, abnormality in laboratory platelet tests, or petechial bleeding \[[@CR3]\].

In a sample of epileptic subjects, May and Sunder \[[@CR14]\] reported thrombocytopenia to be the most frequent adverse event; nevertheless, hematologic toxicity was never severe enough to discontinue therapy and it always improved after small decrements of VPA doses. In Italy, a survey on the safety profile of antiepileptic drugs reported that the highest percentage of hematological reactions (including thrombocytopenia) was related to VPA \[[@CR15]\]. A study with a sample of 126 adult psychiatric patients reported a 5% prevalence of thrombocytopenia (\< 150,000/μL) with a significant increased risk in female subjects in case of serum concentrations \> 80 μg/mL; moreover, every 10 μg/mL increase in serum drug levels was associated with a decrease of 17 units/μL in the platelet count \[[@CR6]\]. Another survey with 264 psychiatric patients reported a 12% prevalence of thrombocytopenia, with the elderly having the highest risk, especially with a VPA dosage \> 1 g/day \[[@CR9]\]. Trannel and colleagues \[[@CR8]\] confirmed in a small sample of 39 psychiatric patients that elderly patients experienced thrombocytopenia more frequently than younger ones during VPA treatment (54 vs 13%). In addition, Nasreddine and Beydoun \[[@CR10]\] reported that about 17.7% of epileptic patients experience at least one episode of thrombocytopenia during VPA treatment, and the risk was significantly increased in case of VPA plasma levels \> 100 μg/mL for women and 130 μg/mL for men. Finally, a recent study by Zighetti and colleagues \[[@CR16]\] failed to find a significant association between chronic VPA treatment and risk of abnormal hemostasis or thrombocytopenia (Table [1](#Tab1){ref-type="table"}).Table 1Valproic acid monotherapy and thrombocytopenia: summary of findingsAuthorsQuality ratingSample sizeStudy designDisorderPrimary objectiveValproate plasma level (μg/mL)Rate of thrombocytopenia (\< 150,000/μL)May and Sunder \[[@CR14]\]260Prospective study. Hematologists were blinded with respect to patients' treatmentEpilepsyRate of hematologic side effects during VPA treatment30--14520% (thrombocytopenia \< 130,000**/**μL)Gidal et al. \[[@CR11]\]227Prospective, controlled studyEpilepsyRate of thrombocytopenia during VPA treatmentNANAConley et al. \[[@CR9]\]^a^3264RetrospectivePsychiatric patientsPrevalence of thrombocytopenia in hospitalized patients receiving VPANA12%Trannel et al. \[[@CR8]\]339RetrospectivePsychiatric inpatientsPrevalence of thrombocytopenia in hospitalized patients receiving VPA16--16128% (total sample)\
54% (elderly patients) (thrombocytopenia \< 100,000**/**μL)De Berardis et al. \[[@CR13]\]225Prospective, controlled studyNew onset bipolar patientsRate of thrombocytopenia during VPA treatment61^b^0%^d^Nasreddine and Beydoun \[[@CR10]\]1265Double-blind, multicenter, prospective studyRefractory partial epilepsyThe evaluation of the relationship between VPA plasma levels and platelet counts13--257\
Increased risk \> 100 for women and \> 130 for men18% (thrombocytopenia \< 100,000**/**μL)Vasudev et al. \[[@CR6]\] (no information about concomitant medication alongside VPA)3126RetrospectivePsychiatric patientsRate of Hematologic side effects during VPA treatment11--138\
Increased risk \> 805%Martínez-Lazcano et al. \[[@CR7]\] (concomitant psychiatric medication as well as VPA)3167Cross-sectionalPsychiatric patientsFrequency of use of VPA in psychiatric patients and rate of relative side effects72^b^18%Zighetti et al. \[[@CR16]\]320 cases, 20 controlsCross-sectionalEpilepsyMeasurement of parameters of primary hemostasis in VPA-treated patients67^c^10% cases (subjects treated with VPA)\
20% controls (healthy subjects or treated with a different antiepileptic)Quality rating was performed according to the following criteria (Qualitative Assessment Tool for Quantitative Studies): (i) selection bias (sample size power and number of subjects who agreed to participate into the study); (ii) study design (randomized versus non-randomized trials); (iii) confounders (yes/no); (iv) blinding (yes/no); (v) data collection methods (self-reported data, observations by investigators or medical records); (vi) presence of description of numbers and reasons for withdrawals and drop-outs. 1 = strong (no weak ratings according to above criteria); 2 = moderate (one weak rating according to above criteria); 3 = weak (two or more weak ratings according to above criteria)*NA* not available, *VPA* valproic acid^a^In this study, patients received polytherapy (valproate plus antidepressants, clozapine, donepezil, aspirin, carbamazepine, heparin, ticlopidine, trimethoprim-sulfamethoxazole). Among patients in treatment with valproate, subjects with thrombocytopenia more frequently received concomitant treatment with aspirin and donepezil^b^Mean plasma concentrations (SD ± 20)^c^Mean plasma concentrations (SD ± 38)^d^Significant decrease of platelet count in bipolar subjects in treatment with valproate than in healthy controls

Conclusions {#Sec4}
===========

VPA is currently considered a first-line treatment option for the management of both BD and different forms of epilepsy in the light of its efficacy and relative safety. More than 40 years of clinical experience have clearly established the common adverse events associated with VPA, including hepatotoxicity and the teratogenic risks. It is very surprising that thrombocytopenia, although considered a common/very common side effect according to the definition by the World Health Organization, has attracted less interest in clinical research despite the important therapeutic implications. Of note, the available data report a prevalence of thrombocytopenia between 5--54% of total patients receiving treatment with VPA (12--18% in studies with a sample size \> 150). The risk factors of VPA-associated thrombocytopenia appear to be advanced age, female gender, and high doses, so clinicians should be particularly cautious in prescribing this compound in elderly female patients, especially in doses \> 1 g/day. It should also be remembered that elderly patients frequently receive multiple therapies that can increase the risk of thrombocytopenia or bleeding (e.g., aspirin or anticoagulants frequently prescribed to the geriatric population). Adjustment of doses seems to partially reverse VPA-associated thrombocytopenia.

Future research should address a number of questions. First, the real clinical risks of VPA-associated thrombocytopenia are unclear; for example, it is not defined whether VPA-associated thrombocytopenia is really associated with an increased risk of life-threatening adverse events such as hemorrhagic stroke. Second, although one study demonstrated similar pharmacokinetic parameters in epileptic and psychiatric patients in the course of VPA therapy \[[@CR17]\], the type of illness may influence the risk of adverse events associated with thrombocytopenia. Patients with BD, independently from treatment with atypical antipsychotics, have a higher frequency of diabetes and metabolic syndrome than the general population \[[@CR2]\], so treatment with VPA may expose bipolar subjects to a further risk of cardiovascular events as a result of thrombocytopenia. Furthermore, patients with a psychiatric disorder are frequently treated with multiple therapies which may increase the risk of bleeding (e.g., selective serotonin reuptake inhibitors). Third, it is not entirely clear how soon hematological abnormalities may appear, so that short-term therapy (such as during a manic episode) may have a limited effect compared with chronic prophylaxis \[[@CR14]\]. Also, a different pharmacological formulation (intravenous versus oral) may impact differently on the risk of thrombocytopenia. Finally, the exact mechanism of valproate-associated thrombocytopenia should be clarified with the aim to carry out preventive strategies for this adverse event as well as to identify high-risk populations.
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